Vaccine Info

mRNA-1574 HIV Vaccine

Authored by
Staff
Last reviewed
January 16, 2023
Fact checked by
Robert Carlson, MD
Share

Moderna mRNA-1574 HIV Vaccine Candidate 2023

Moderna Inc. HIV mRNA vaccine candidate mRNA-574 is being evaluated with IAVI, Scripps Research, and the U.S. National Institutes of Health (NIH) to test and compare multiple native-like HIV env trimer antigens. The mRNA-1574 HIV vaccine is based on Moderna's mRNA platform and utilizes multiple mRNAs encoded native-like HIV trimers to induce sustained protective levels of HIV-neutralizing antibodies.

The envelope trimers were developed by William Schief, Ph.D., and colleagues. Dr. Schief is a professor at Scripps Research and executive director of vaccine design at IAVI's California-based Neutralizing Antibody Center

Moderna launched an open-label, multicenter, randomized phase 1 clinical study in 2022 to evaluate the safety and immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV trimer vaccine candidates. Last Update Posted: October 3, 2022.

Moderna is also collaborating in the Phase 1 Study Evaluating the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core). Last Update Posted: September 26, 2022

Massachusetts-based Moderna Inc. says, 'Since our founding in 2010, we have worked to build the industry's leading mRNA technology platform.'

HIV Vaccine Indication

38.4 million [33.9 million–43.8 million] people globally were living with HIV, and about 70% of them live in Africa. And 650,000 [510,000–860 000] people died from AIDS-related illnesses in 2021. Furthermore, nearly 6 million people did not know they were living with HIV. Women accounted for 49% of all new infections in 2021.

mRNA-1574 Vaccine News 2022-2023

December 13, 2022 - The U.S. NIH published an article: Progress toward an eventual HIV vaccine.

May 4, 2022  - Moderna Inc. confirmed the Phase 1 study of mRNA-1574 is ongoing.

March 14, 2022 - Moderna announced the had begun their Phase 1 clinical trial of its HIV Trimer mRNA vaccine candidate.

mRNA-1574 Vaccine Clinical Trials

As of October 3, 2022, the Phase 1 clinical trial NCT05217641 was updated: A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants. This trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and elicit autologous neutralizing antibodies. The trial is expected to enroll approximately 100 HIV-negative adults aged 18 to rs.